Cargando…
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
BACKGROUND: The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutated ovari...
Autores principales: | Ma, Yana, Liu, Jiale, Li, Ning, Bu, Hualei, Huang, Yongwen, Jin, Chengjuan, Wen, Hao, Feng, Shuai, Zhang, Hui, Yang, Xiaorong, Kong, Beihua, Wu, Lingying, Song, Kun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612277/ https://www.ncbi.nlm.nih.gov/pubmed/37891662 http://dx.doi.org/10.1186/s13048-023-01283-2 |
Ejemplares similares
-
Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021) -
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022) -
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020) -
Targeting poly(ADP-ribose) polymerase activity for cancer therapy
por: Mégnin-Chanet, Frédérique, et al.
Publicado: (2010) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)